Spots Global Cancer Trial Database for tumor, solid
Every month we try and update this database with for tumor, solid cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours. | NCT06193902 | Tumor, Solid | LEU011 | 18 Years - | Leucid Bio | |
| Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors | NCT03454035 | Tumor, Solid Pancreatic Canc... Melanoma | Ulixertinib Palbociclib | 18 Years - 99 Years | UNC Lineberger Comprehensive Cancer Center | |
| A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab | NCT05378425 | Cancer Tumor, Solid Advanced Solid ... Metastatic Canc... Locally Advance... | NTX-1088 Pembrolizumab | 18 Years - | Nectin Therapeutics Ltd | |
| 18F-AlF-FAPi-04 PET/CT Imaging in Patients With Solid Tumor | NCT06126705 | Tumor, Solid | Radiation: 18F-... Radiation: 18F-... | 18 Years - | Affiliated Hospital of North Sichuan Medical College | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors | NCT05108623 | Tumor, Solid | agenT-797 Approved ICIs | 18 Years - | MiNK Therapeutics | |
| Varian ProBeam Proton Therapy System China Clinical Trial (Guangzhou) | NCT06338436 | Tumor, Solid | Proton Radiatio... | 18 Years - 80 Years | Varian, a Siemens Healthineers Company | |
| A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors | NCT05108623 | Tumor, Solid | agenT-797 Approved ICIs | 18 Years - | MiNK Therapeutics | |
| 68Ga-FAPI-46 PET for Imaging of FAP Expressing Cancer | NCT05160051 | Tumor, Solid | 68Ga-FAPI-46 PE... | 18 Years - | University Hospital, Essen | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| Performance and Safety of Biology-Guided Radiotherapy Using the RefleXion Medical Radiotherapy System (BIOGUIDE-X) | NCT04788147 | Cancer Tumor, Solid Cancer, Lung Cancer, Bone Metastasis to L... Metastasis to B... | RMRS IDE Device | 22 Years - | RefleXion Medical | |
| Phase II Study of Intensity Modulated Radiotherapy in Dose Painting for Sinus Carcinomas After Endoscopic Surgery | NCT05943119 | Tumor, Solid | Radiotherapy in... Standard pan-si... | 18 Years - | Centre Francois Baclesse | |
| 68Ga-FAPI-RGD PET/CT for Dual Integrin αvβ3 and FAP-targeted Imaging in Patients With Various Types of Cancer and Compared With 18F-FDG | NCT05543317 | Tumor, Solid Positron-Emissi... | 18F-FDG PET/CT,... | 18 Years - 90 Years | The First Affiliated Hospital of Xiamen University | |
| Varian ProBeam Proton Therapy System Clinical Trial (Shandong) | NCT06340815 | Tumor, Solid | Radiation: Prot... | 18 Years - 80 Years | Varian, a Siemens Healthineers Company | |
| Autologous TLPO Vaccine Basket | NCT06175221 | Tumor, Solid Tumor Metastasi... Cancer Tumor | Tumor lysate, p... | 18 Years - | Elios Therapeutics, LLC | |
| Home Management of Simple Hydromorphone PCA Pump Mode | NCT05744089 | Cancer Pain Tumor, Solid Carcinoma | PCA pump | 18 Years - | The First Affiliated Hospital of Xinxiang Medical College | |
| Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors | NCT03454035 | Tumor, Solid Pancreatic Canc... Melanoma | Ulixertinib Palbociclib | 18 Years - 99 Years | UNC Lineberger Comprehensive Cancer Center | |
| A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab | NCT05378425 | Cancer Tumor, Solid Advanced Solid ... Metastatic Canc... Locally Advance... | NTX-1088 Pembrolizumab | 18 Years - | Nectin Therapeutics Ltd | |
| Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer | NCT05620134 | Cancer Tumor, Solid Advanced Solid ... Metastatic Canc... Melanoma Colorectal Canc... Non-small Cell ... Small-cell Lung... Urothelial Carc... Squamous Cell C... Luminal Breast ... Triple Negative... Clear Cell Rena... Papillary Renal... Gastric Adenoca... GastroEsophagea... Squamous Cell C... Pancreatic Aden... Hepatocellular ... Colorectal Aden... Epithelial Ovar... Thyroid Cancer | JK08 Pembrolizumab | 18 Years - | Salubris Biotherapeutics Inc | |
| Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor | NCT03985072 | Tumor, Solid Gall Bladder Ca... Cervical Cancer Gastric Cancer Pancreatic Canc... Colorectal Canc... | Andes-1537 for ... | 18 Years - | Andes Biotechnologies | |
| A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | NCT05094804 | Cancer Tumor, Solid Malignant Neopl... Metastatic Canc... Advanced Solid ... Non Small Cell ... Melanoma Head and Neck S... Leiomyosarcoma Liposarcoma | OR2805 Cemiplimab Docetaxel | 18 Years - | OncoResponse, Inc. | |
| A Study of Tumor Neoantigen-specific T Cells in the Treatment of Advanced Solid Tumors | NCT06431529 | Tumor, Solid | tumor neoantige... | 18 Years - 75 Years | Jinling Hospital, China | |
| Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients | NCT05974410 | Glioblastoma Squamous Cell C... Hodgkin Lymphom... Non-hodgkin Lym... Breast Cancer Prostate Cancer Gastric Cancer Ovarian Cancer Acute Leukemia Pancreatic Canc... Spindle Cell Sa... Cancer Tumor, Solid Tumor, Brain | AVM0703 Hydrocortisone Proton pump inh... | - | AVM Biotechnology Inc | |
| First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors | NCT04528836 | Tumor, Solid | BBP-398 (Former... | 18 Years - | Navire Pharma Inc., a BridgeBio company | |
| BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab | NCT03486301 | Tumor, Solid | BDB001 Pembrolizumab | 18 Years - | Eikon Therapeutics | |
| BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab | NCT04196530 | Tumor, Solid | BDB001 Atezolizumab | 18 Years - | Eikon Therapeutics | |
| First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors | NCT04528836 | Tumor, Solid | BBP-398 (Former... | 18 Years - | Navire Pharma Inc., a BridgeBio company | |
| Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies | NCT04640246 | Cancer Tumor, Solid Refractory Canc... | TBX-3400 | 18 Years - | Taiga Biotechnologies, Inc. | |
| Follow-up of Actual Patient Care Site Two Months After Hospitalisation Compared With Their Expressed Choice Regarding Subsequent Care Site (RESPECT) | NCT04628234 | Hematologic Mal... Tumor, Solid | 18 Years - | Institut de cancérologie Strasbourg Europe | ||
| 68Ga-FAPI-RGD PET/CT for Dual Integrin αvβ3 and FAP-targeted Imaging in Patients With Various Types of Cancer and Compared With 18F-FDG | NCT05543317 | Tumor, Solid Positron-Emissi... | 18F-FDG PET/CT,... | 18 Years - 90 Years | The First Affiliated Hospital of Xiamen University | |
| Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies | NCT04640246 | Cancer Tumor, Solid Refractory Canc... | TBX-3400 | 18 Years - | Taiga Biotechnologies, Inc. | |
| Varian ProBeam Proton Therapy System China Clinical Trial (Guangzhou) | NCT06338436 | Tumor, Solid | Proton Radiatio... | 18 Years - 80 Years | Varian, a Siemens Healthineers Company | |
| BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab | NCT04196530 | Tumor, Solid | BDB001 Atezolizumab | 18 Years - | Eikon Therapeutics | |
| Immune Profiling for Cancer Immunotherapy Response | NCT06116032 | Cancer Tumor, Solid Hematologic Mal... Blood Cancer | Methylation Cyt... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Comaprison of 68Ga-FAP-2286 and 18F-FDG PET/CT in Patients With Various Types of Cancer | NCT05392205 | Tumor, Solid Positron-Emissi... | 18F-FDG | 18 Years - | The First Affiliated Hospital of Xiamen University | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors | NCT03491631 | Tumor, Solid Cancer, Metasta... Neoplasm Malign... | SHR9146+SHR-121... SHR9146+SHR-121... | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab | NCT03486301 | Tumor, Solid | BDB001 Pembrolizumab | 18 Years - | Eikon Therapeutics | |
| Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors | NCT03911557 | Tumor, Solid | Durvalumab and ... | 18 Years - | University of Kentucky | |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) | NCT05103358 | Tumor Tumor, Solid Metastasis Metastatic Canc... Cancer Cancer Metastat... Tumors Neoplasms Neoplasm Metast... Solid Tumor Advanced Solid ... Advanced Cancer Malignant Solid... Malignant Solid... Malignant Neopl... Malignant Tumor TSC TSC1 TSC2 Metastatic Soli... Metastatic Neop... | nab-sirolimus | 12 Years - | Aadi Bioscience, Inc. | |
| A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents | NCT06090266 | Cancer Tumor, Solid Malignant Neopl... Metastatic Canc... Advanced Solid ... Platinum-resist... Cutaneous Squam... | OR502 Cemiplimab | 18 Years - | OncoResponse, Inc. | |
| Home Management of Simple Hydromorphone PCA Pump Mode | NCT05744089 | Cancer Pain Tumor, Solid Carcinoma | PCA pump | 18 Years - | The First Affiliated Hospital of Xinxiang Medical College | |
| A Study of Tumor Neoantigen-specific T Cells in the Treatment of Advanced Solid Tumors | NCT06431529 | Tumor, Solid | tumor neoantige... | 18 Years - 75 Years | Jinling Hospital, China | |
| The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy | NCT05432232 | Renal Cancer Tumor, Solid Kidney Cancer Tumor Tumor, Benign Kidney Neoplasm... | HistoSonics Inv... | 18 Years - | HistoSonics, Inc. | |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) | NCT05103358 | Tumor Tumor, Solid Metastasis Metastatic Canc... Cancer Cancer Metastat... Tumors Neoplasms Neoplasm Metast... Solid Tumor Advanced Solid ... Advanced Cancer Malignant Solid... Malignant Solid... Malignant Neopl... Malignant Tumor TSC TSC1 TSC2 Metastatic Soli... Metastatic Neop... | nab-sirolimus | 12 Years - | Aadi Bioscience, Inc. | |
| BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors | NCT04819373 | Tumor, Solid | BDB001 | 18 Years - | Eikon Therapeutics | |
| Varian ProBeam Proton Therapy System Clinical Trial (Shandong) | NCT06340815 | Tumor, Solid | Radiation: Prot... | 18 Years - 80 Years | Varian, a Siemens Healthineers Company | |
| Phase II Study of Intensity Modulated Radiotherapy in Dose Painting for Sinus Carcinomas After Endoscopic Surgery | NCT05943119 | Tumor, Solid | Radiotherapy in... Standard pan-si... | 18 Years - | Centre Francois Baclesse | |
| A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | NCT05094804 | Cancer Tumor, Solid Malignant Neopl... Metastatic Canc... Advanced Solid ... Non Small Cell ... Melanoma Head and Neck S... Leiomyosarcoma Liposarcoma | OR2805 Cemiplimab Docetaxel | 18 Years - | OncoResponse, Inc. | |
| Analysis of Chemical Pattern Exhaled by Different Neoplasms Through Chemoresistive Nanostructured Sensors | NCT03929185 | Tumor, Solid | blood analysis ... tissue analysis... | 18 Years - | University Hospital of Ferrara | |
| Varian ProBeam360° Proton Therapy System China Clinical Trial (Wuhan) | NCT06347731 | Tumor, Solid | Proton Radiatio... | 18 Years - 80 Years | Varian, a Siemens Healthineers Company | |
| A Study of Tumor Neoantigen-specific T Cells in the Treatment of Advanced Solid Tumors | NCT06431529 | Tumor, Solid | tumor neoantige... | 18 Years - 75 Years | Jinling Hospital, China | |
| Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment | NCT05661461 | Tumor, Solid Tumor Advanced Solid ... | nab-sirolimus | 18 Years - | Aadi Bioscience, Inc. | |
| Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies | NCT05221320 | Tumor, Solid Gastrointestina... | Ulixertinib Hydroxychloroqu... | 18 Years - | BioMed Valley Discoveries, Inc | |
| BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab | NCT04196530 | Tumor, Solid | BDB001 Atezolizumab | 18 Years - | Eikon Therapeutics | |
| An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors | NCT04443088 | Cancer Solid Tumor, Ad... Cancer Metastat... Solid Carcinoma Solid Tumor, Un... Tumor, Solid | INV-1120 Pembrolizumab | 18 Years - | Shenzhen Ionova Life Sciences Co., Ltd. | |
| A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001) | NCT01358331 | Tumor, Solid | MK-8353 | 18 Years - | Merck Sharp & Dohme LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
